Latest data on humoral immune response to the SARS-CoV-2 vaccine in hemodialysis and transplant patients

Interview with Andreas Kribben, Essen, Germany

Two new studies from Germany showed that antibody titer levels of transplant patients and older hemodialysis patients are not as high as in healthy controls. Does this have any clinical implications? And what does this mean for the daily life of vaccinated patients on dialysis or for kidney transplant recipients? How can we protect these patients against COVID-19 after vaccination? We asked these questions to Andreas Kribben, one of the authors of the new studies.

Read the interview
Publications you should not miss!

How long should RRT be delayed in critically ill patients?
Continuing to delay renal replacement therapy (RRT) not only has no additional benefit, but is also associated with potential harm in severe acute kidney injury (AKI) with oliguria for > 72 hours or blood urea nitrogen concentration (BUN) > 112 mg/dL, and no severe complication mandating immediate RRT. [Read more]

The Decade of the Kidney: a call to action
A position paper from the European Kidney Health Alliance (EKHA) and stakeholders including patients has issued a call for action emphasizing the importance of reducing the heavy and rapidly growing burden of kidney disease. The aim is to raise awareness among European governments and general public of the urgent need to invest in research for kidney health during the Decade of the Kidney (2020-30). [Read more]

Improving treatment of distal tubular renal acidosis: guidance from ERKNet/ESPN
Distal renal tubular acidosis (dRTA) is a rare genetic disease characterized by impaired ability of the distal tubule to excrete acid. Practice Points from ERKNet/ESPN aim to raise awareness and provide management guidance to improve treatment and establish an initial best practice standard against which treatment can be audited. [Read more]

Long-term risks after living kidney donation: how to inform potential donors?
A survey from the ERA-EDTA DESCARTES and EKITA transplantation working groups reveals wide variation and no uniform standard in how often potential donors are informed of long-term risks of living kidney donation. This is the largest-ever study on this topic and the only survey to describe current professional practice in light of accumulating evidence of long-term risks of kidney donation. [Read more]

Vadadustat achieves target Hb concentrations, but risk remains unclear
Large randomized controlled trials in chronic kidney disease (CKD) patients with anemia show that vadadustat is noninferior to darbepoetin alfa in achieving recommended target hemoglobin (Hb). However, there may be concerns about cardioiological safety in non-dialysis-dependent CKD. [Read more]
The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA in compliance with the EU General Data Protection Regulation (2016/679).

Unsubscribe

© 2021 ERA-EDTA